Safety Study of AB0024 in Patients With Advanced Solid Tumors
| Status: | Archived |
|---|---|
| Conditions: | Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | July 2010 |
| End Date: | November 2012 |
A Phase 1, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AB0024 in Adult Patients With Advanced Solid Tumors
This is a first-in-human, open-label, sequential dose escalation study to evaluate AB0024 in
patients with advanced solid tumors.
Patients will receive four infusions of AB0024 every two weeks starting on Day 1 until Day
43. Patients will be seen weekly for safety assessments and collection of blood samples
until Day 71. Patients who do not show evidence of disease progression by clinical
assessment or by CT or MRI prior to Day 71 may continue receiving AB0024 every 2 weeks
starting on Day 71 until disease progression (clinical or radiographic), study drug
intolerance, or withdrawal of consent.
We found this trial at
2
sites
4201 St Antoine St
Detroit, Michigan 48201
Detroit, Michigan 48201
(313) 577-1429
Wayne State University/Detroit Medical Center Founded in 1868, the Wayne State University School of Medicine...
Click here to add this to my saved trials
Click here to add this to my saved trials